Antitumor activity of Oncolytic Herpes Symplex Virus Type 1 and photodynamic therapy in in vitro preclinical models of glioblastoma
BACKGROUND: Glioblastoma (GBM) remains the most aggressive primary brain tumor in adults, with limited therapeutic options and inevitable recurrence despite maximal standard-of-care treatment. Photodynamic therapy (PDT) and oncolytic virotherapy have independently shown promise as alternative approaches, yet their combined potential in GBM remains incompletely explored. METHODS: We engineered a highly neuroattenuated herpes simplex virus type 1-based oncolytic virus (oHSV1), genetically related to talimogene laherparepvec (T-VEC), to express the photosensitizer KillerRed (KR) targeted to the cell plasma membrane (memKR). The cytolytic activity of this recombinant virus was evaluated in multiple human and murine GBM cell lines, patient-derived GBM cells, and three-dimensional (3D) spheroid models. We further assessed whether photoactivation of virus-encoded memKR or of the chemical photosensitizer phthalocyanine could enhance oHSV1-mediated cytotoxicity, including in spheroids infected via monocyte-based viral delivery. RESULTS: The recombinant memKR-encoding virus (oHSV1-KR) efficiently infected and killed GBM cells across 2D and 3D culture systems. Photoactivation of memKR significantly enhanced virus-mediated cytotoxicity in patient-derived GBM spheroids, particularly at lower viral doses. Similarly, phthalocyanine photoactivation augmented oHSV1-induced cell death, accelerating loss of viability in both monolayer cultures and spheroids. Monocyte-mediated delivery of oHSV1-KR resulted in effective viral transfer to GBM spheroids and retained responsiveness to photodynamic activation. CONCLUSIONS: These findings demonstrate that combining oHSV1-based virotherapy with photodynamic activation enhances cytotoxic efficacy in advanced preclinical models of GBM. While limited to in vitro and ex vivo systems, this work establishes a modular and controllable therapeutic platform and provides a foundation for future in vivo and immunological studies aimed at translational development.
Authors
- Fabio Mammano (ORCID: https://orcid.org/0000-0003-3751-1691)
- Arianna Calistri (ORCID: https://orcid.org/0000-0002-6881-7936)
- Daniela Marazziti (ORCID: https://orcid.org/0000-0002-1582-9271)
- Cristina Parolin
- Elena Rampazzo (ORCID: https://orcid.org/0000-0002-5232-757X)
- Luca Persano (ORCID: https://orcid.org/0000-0002-0050-3666)
- Ana Gabriela de Oliveira do Rêgo (ORCID: https://orcid.org/0000-0003-0093-9379)
- Viola Donati (ORCID: https://orcid.org/0000-0002-5854-3089)
- Alberto Reale (ORCID: https://orcid.org/0000-0003-1737-8635)
- Chiara Di Pietro (ORCID: https://orcid.org/0000-0002-2680-1821)
- Mariateresa Panarelli
- Maria Vittoria Fornaini
- Alessandra Rossetto
Institutions
- University of Padua (IT)
- Veneto Institute of Molecular Medicine (IT)
- Institute of Cell Biology and Neurobiology (IT)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2026-05-27
- DOI
- https://doi.org/10.1186/s12967-026-08329-1
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fondazione Cassa di Risparmio di Padova e Rovigo
- Associazione Italiana per la Ricerca sul Cancro